In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss strategies for monitoring and managing treatment-related adverse events over time in patients receiving adjuvant therapy for early-stage EGFR-mutated nonโsmall cell lung cancer (NSCLC). Dr. Leal emphasizes the importance of proactive and continuous monitoring, particularly for common toxicities such as dermatologic reactions and gastrointestinal side effects. The discussion highlights the value of early intervention, patient education, and routine follow-up to identify and address adverse events before they impact adherence. Dr. Leal also notes that appropriate dose modifications, when necessary, can help maintain patients on therapy without compromising tolerability. The conversation reinforces the importance of maintaining open communication with patients to ensure that side effects are reported and managed promptly. This segment underscores how effective long-term toxicity management supports adherence and helps patients complete the intended course of therapy in EGFR-mutated NSCLC.
